FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W224280792> ?p ?o ?g. }

• W224280792 endingPage "307" @default.
• W224280792 startingPage "288" @default.
• W224280792 abstract "Digestive tract tumors are among the most common and deadliest malignancies worldwide, mainly due to late diagnosis and lack of efficient therapeutics. Current treatments essentially rely on surgery associated with (neo)adjuvant chemotherapy agents. Despite an upfront response, conventional drugs often fail to eliminate highly aggressive clones endowed with chemoresistant properties, which are responsible for tumor recurrence and disease dissemination. Synthetic drugs also present severe adverse systemic effects, hampering the administration of biologically effective dosages. Nanoencapsulation of chemotherapeutic agents within biocompatible polymeric or lipid matrices holds great potential to improve the pharmacokinetics and efficacy of conventional chemotherapy while reducing systemic toxicity. Tagging nanoparticle surfaces with specific ligands for cancer cells, namely monoclonal antibodies or antibody fragments, has provided means to target more aggressive clones, further improving the selectivity and efficacy of nanodelivery vehicles. In fact, over the past twenty years, significant research has translated into a wide array of guided nanoparticles, providing the molecular background for a new generation of intelligent and more effective anti-cancer agents. Attempting to bring awareness among the medical community to emerging targeted nanopharmaceuticals and foster advances in the field, we have conducted a systematic review about this matter. Emphasis was set on ongoing preclinical and clinical trials for liver, colorectal, gastric and pancreatic cancers. To the best of our knowledge this is the first systematic and integrated overview on this field. Using a specific query, 433 abstracts were gathered and narrowed to 47 manuscripts when matched against inclusion/exclusion criteria. All studies showed that active targeting improves the effectiveness of the nanodrugs alone, while lowering its side effects. The main focus has been on hepatocarcinomas, mainly by exploring glycans as homing molecules. Other ligands such as peptides/small proteins and antibodies/antibody fragments, with affinity to either tumor vasculature or tumor cells, have also been widely and successfully applied to guide nanodrugs to gastrointestinal carcinomas. Conversely, few solutions have been presented for pancreatic tumors. To this date only three nanocomplexes have progressed beyond pre-clinical stages: i) PK2, a galactosamine-functionalized polymeric-DOX formulation for hepatocarcinomas; ii) MCC-465, an anti-(myosin heavy chain a) immunoliposome for advanced stage metastatic solid tumors; and iii) MBP-426, a transferrin-liposome-oxaliplatin conjugate, also for advanced stage tumors. Still, none has been approved for clinical use. However, based on the high amount of pre-clinical studies showing enthusiastic results, the number of clinical trials is expected to increase in the near future. A more profound understanding about the molecular nature of chemoresistant clones and cancer stem cell biology will also contribute to boost the field of guided nanopharmacology towards more effective solutions." @default.
• W224280792 created "2016-06-24" @default.
• W224280792 creator A5030200432 @default.
• W224280792 creator A5030567793 @default.
• W224280792 creator A5035096310 @default.
• W224280792 creator A5039318337 @default.
• W224280792 creator A5041458969 @default.
• W224280792 creator A5073487168 @default.
• W224280792 creator A5086970300 @default.
• W224280792 date "2015-07-01" @default.
• W224280792 modified "2023-10-07" @default.
• W224280792 title "New trends in guided nanotherapies for digestive cancers: A systematic review" @default.
• W224280792 cites W1007490150 @default.
• W224280792 cites W1493048246 @default.
• W224280792 cites W1526451509 @default.
• W224280792 cites W1690464810 @default.
• W224280792 cites W171233943 @default.
• W224280792 cites W1821391444 @default.
• W224280792 cites W1939364580 @default.
• W224280792 cites W1965067289 @default.
• W224280792 cites W1965135835 @default.
• W224280792 cites W1966310613 @default.
• W224280792 cites W1966535050 @default.
• W224280792 cites W1966961208 @default.
• W224280792 cites W1968029051 @default.
• W224280792 cites W1969349969 @default.
• W224280792 cites W1969951885 @default.
• W224280792 cites W1970038366 @default.
• W224280792 cites W1970239046 @default.
• W224280792 cites W1974523261 @default.
• W224280792 cites W1975174876 @default.
• W224280792 cites W1977614672 @default.
• W224280792 cites W1978872101 @default.
• W224280792 cites W1979109871 @default.
• W224280792 cites W1981380764 @default.
• W224280792 cites W1981421409 @default.
• W224280792 cites W1982068200 @default.
• W224280792 cites W1982536129 @default.
• W224280792 cites W1984987343 @default.
• W224280792 cites W1986418258 @default.
• W224280792 cites W1988318590 @default.
• W224280792 cites W1988567685 @default.
• W224280792 cites W1990455420 @default.
• W224280792 cites W1993778590 @default.
• W224280792 cites W1993802093 @default.
• W224280792 cites W1994236074 @default.
• W224280792 cites W1995747060 @default.
• W224280792 cites W1999204999 @default.
• W224280792 cites W1999433592 @default.
• W224280792 cites W1999635013 @default.
• W224280792 cites W2002663625 @default.
• W224280792 cites W2007514493 @default.
• W224280792 cites W2009319584 @default.
• W224280792 cites W2011090397 @default.
• W224280792 cites W2011217812 @default.
• W224280792 cites W2011690386 @default.
• W224280792 cites W2012276721 @default.
• W224280792 cites W2013470095 @default.
• W224280792 cites W2015006203 @default.
• W224280792 cites W2015561372 @default.
• W224280792 cites W2015700471 @default.
• W224280792 cites W2015931009 @default.
• W224280792 cites W2016834188 @default.
• W224280792 cites W2017974015 @default.
• W224280792 cites W2018693859 @default.
• W224280792 cites W2020398834 @default.
• W224280792 cites W2021818592 @default.
• W224280792 cites W2023568521 @default.
• W224280792 cites W2023999240 @default.
• W224280792 cites W2027137358 @default.
• W224280792 cites W2027178679 @default.
• W224280792 cites W2027437657 @default.
• W224280792 cites W2027828682 @default.
• W224280792 cites W2028294113 @default.
• W224280792 cites W2028893730 @default.
• W224280792 cites W2029039082 @default.
• W224280792 cites W2029773366 @default.
• W224280792 cites W2031461934 @default.
• W224280792 cites W2031630601 @default.
• W224280792 cites W2032036028 @default.
• W224280792 cites W2035015065 @default.
• W224280792 cites W2035054580 @default.
• W224280792 cites W2035338985 @default.
• W224280792 cites W2035987019 @default.
• W224280792 cites W2036203878 @default.
• W224280792 cites W2037876225 @default.
• W224280792 cites W2039058362 @default.
• W224280792 cites W2039828110 @default.
• W224280792 cites W2041489148 @default.
• W224280792 cites W2041521061 @default.
• W224280792 cites W2041685488 @default.
• W224280792 cites W2041759339 @default.
• W224280792 cites W2042607152 @default.
• W224280792 cites W2042838617 @default.
• W224280792 cites W2043282529 @default.
• W224280792 cites W2045269005 @default.
• W224280792 cites W2049515588 @default.
• W224280792 cites W2049886572 @default.

• next